Lobular carcinoma in situ

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's weight loss doctor NYC
Philadelphia GLP-1 weight loss and GLP-1 clinic NYC

Lobular carcinoma in situ
File:Diagram showing lobular carcinoma in situ (LCIS) CRUK 166.svg
Synonyms	Lobular neoplasia
Pronounce	N/A
Specialty	N/A
Symptoms	Usually none, sometimes breast lump
Complications	Increased risk of breast cancer
Onset	Typically between ages 40-50
Duration	Long-term
Types	Classic, pleomorphic
Causes	Unknown
Risks	Family history of breast cancer, hormonal factors
Diagnosis	Biopsy
Differential diagnosis	Ductal carcinoma in situ, atypical lobular hyperplasia
Prevention	Risk-reducing mastectomy, chemoprevention
Treatment	Surveillance, surgery, hormonal therapy
Medication	N/A
Prognosis	Generally good, but increased risk of invasive cancer
Frequency	0.5-3.8% of all breast biopsies
Deaths	N/A

Lobular carcinoma in situ (LCIS) is a condition in which abnormal cells are found in the lobules of the breast. Despite its name, LCIS is not considered a true breast cancer, but rather a marker indicating an increased risk of developing breast cancer later in life. LCIS is often discovered incidentally during a biopsy for another reason, as it typically does not present with a palpable lump or show up on a mammogram.

Diagnosis

The diagnosis of LCIS is usually made following a biopsy of the breast tissue, often performed for unrelated reasons, as LCIS itself does not usually produce symptoms or abnormalities on imaging studies. Histologically, LCIS is characterized by a proliferation of small, uniform cells that fill and expand the lobular units of the breast. These cells typically exhibit minimal atypia and do not breach the basement membrane, distinguishing LCIS from invasive lobular carcinoma.

Risk Factors

While the exact cause of LCIS is not known, several risk factors have been identified. These include a family history of breast cancer, particularly in first-degree relatives, and certain genetic mutations. Hormonal factors, such as early menarche, late menopause, and use of hormone replacement therapy, may also play a role.

Management

The management of LCIS is focused on surveillance and risk reduction. Options include close monitoring with regular mammograms and clinical breast exams, chemoprevention with anti-estrogen medications such as tamoxifen, and prophylactic surgery for those at very high risk. The choice of management strategy is individualized based on the patient's risk factors and preferences.

Prognosis

While LCIS itself is not cancerous and does not metastasize, individuals with LCIS have a 7-12 times higher risk of developing invasive breast cancer in either breast, compared to the general population. The prognosis for patients with LCIS who develop breast cancer is similar to that of the general population with breast cancer, emphasizing the importance of surveillance and early detection.

See Also

• Breast cancer
• Invasive lobular carcinoma
• Mammography
• Biopsy